Lactobacillus johnsonii as Next Generation Probiotics

Next-generation probiotics (NGPs) have emerged as new preventive and therapeutic tools. NGP is a “well-characterized probiotic strain which could be used as delivery vehicles for a specific molecule abrogating the disease phenotype and thus promoting Health”. Traditional probiotics, such as Lactobacillus johnsonii (L. johnsonii), are good candidates for NGPs to be developed as live biotherapeutic products (LBP). Creative Biolabs offers well-established and innovative One-Stop-Shop LBP development solutions. We can make your LBP-journey easier.

Introduction of L. johnsonii

L. johnsonii formerly known as Lactobacillus acidophilus, isolated several years ago, is a unique strain of bacteria with enhanced adherence properties to the intestinal epithelial monolayer, preventing colonization of potentially pathogenic bacteria. It is one of the many microorganisms that reside in the human intestine. Like all species of the Lactobacillus genus, it is an anaerobic, Gram-positive bacterium, which has a rod-like shape and does not undergo spore formation. The cell surface of L. johnsonii contains various types of cell-surface proteins which are important in helping the microorganism attach to the mucosal surfaces of the GI tract.

The <em>L. johnsonii</em>. <em>L. johnsonii</em>for Disease Treatment Fig.1 The L. johnsonii. L. johnsoniifor Disease Treatment

To investigate the effect of L. johnsonii BS15 on NAFLD, 120 male ICR mice were randomly divided into four groups and administrated with BS15 (2×107cfu/0.2 mL or 2×108cfu/0.2 mL) or phosphate buffered saline (PBS) throughout a 17-week experimental period. Results showed that BS15-treated HFD mice were protected from hepatic steatosis and hepatocyte apoptosis. BS15 exhibited a positive effect on liver lipid peroxidation through an anti-oxidative stress activity by enhancing the liver antioxidant defense system. BS15 also reduced the level of serum lipopolysaccharide in NAFLD mice by lowering the intestinal permeability and adjusting gut flora, followed by the downregulation of the TNFα mRNA level in liver and the serum level of C-reactive protein. These findings suggest that BS15 may be effective in preventing NAFLD induced by HFD.

  • Vaginosis

Hydrogen peroxide-producing lactic acid bacteria (LAB) were isolated from women's vaginas and their anti-inflammatory effects against Gardnerella vaginalis-induced vaginosis were examined in β-estradiol immunosuppressed mice. Of the LABs examined, L. johnsonii HY7042 most potently inhibited G. vaginalis-induced vaginosis. This LAB also inhibited the expressions of IL-1β, IL-6, TNF-α, COX-2, and iNOS, and the activation of NF-κB in vaginal tissues, but increased IL-10 expression. These findings suggest thatL. johnsonii inhibits bacterial vaginosis by inhibiting the expressions of COX-2, iNOS, IL-1β, and TNF-α by regulating NF-κB activation and by killing G. vaginalis, and that L. johnsonii could ameliorate bacterial vaginosis.

The <em>L. johnsonii</em>. <em>L. johnsonii</em>for Disease Treatment Fig.2 Effect of L. johnsonii HY7042 on the adhesion of G. vaginalis to HeLa cells. (Joo, 2011)

What Services Can We Provide for L. johnsoniiat Creative Biolabs?

L. johnsonii Related Products at Creative Biolabs

  • Strain Products

We supply a variety of L. johnsonii strains of different preservation numbers as below. If you need other strains, please contact us.

  • Customized strain culture supernatant. (e.g.: for animal research)
  • Customized strain lyophilized powder containing certain CFU. (e.g.: for animal research)

Creative Biolabs is 100% dedicated to the LBP industry. We will work with you as part of your team to not only provide comprehensive quality data but also timely and effective solutions to any challenges that you face. If you are interested in our L. johnsonii related services and products, please feel free to contact us for further discussion.


  1. Joo, H.M.; et al. Lactobacillus johnsonii HY7042 ameliorates Gardnerella vaginalis-induced vaginosis by killing Gardnerella vaginalis and inhibiting NF-κB activation. International immunopharmacology. 2011, 11(11): 1758-1765.

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Online Inquiry

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Contact us

Live Biotherapeutic

Contact us

Copyright © 2024 Creative Biolabs. All Rights Reserved.

Inquiry Basket